Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemic

Charles Whittaker,Gregory Barnsley,Daniela Olivera Mesa,Daniel J Laydon,Chee Wah Tan,Feng Zhu,Rob Johnson,Patrick Doohan,Gemma Nedjati-Gilani,Peter Winskill,Alexandra Hogan,Arminder Deol,Christinah Mukandavire,Katharina Hauck,David Chien Boon Lye,Lin-Fa Wang,Oliver John Watson,Azra Ghani

DOI: https://doi.org/10.1101/2024.08.12.24311730

2024-08-12

Abstract:COVID-19 has underscored the need for more timely access to vaccines during future pandemics. This has motivated development of broad-spectrum vaccines providing protection against viral families, which could be stockpiled ahead of an outbreak and deployed rapidly following detection. We use mathematical modelling to evaluate the utility of a broadly protective sarbecovirus vaccine (BPSV) during a hypothetical SARS-X outbreak, including ring-vaccination, spatial targeting and mass vaccination of high-risk populations. Our results show BPSV ring- or spatially-targeted vaccination strategies are unlikely to contain a SARS-CoV-2-like virus but could contain or slow the spread of a SARS-CoV-1-like virus. Vaccination of high-risk populations with the BPSV ahead of a virus-specific vaccine (VSV) becoming available could substantially reduce mortality. For a 250-day VSV development timeline, BPSV availability reduced infection-related deaths in our model by 54% on average, though exact impact depended on the non-pharmaceutical intervention (NPI) scenario considered. We further show that BPSV availability enables shorter and less stringent NPIs to be imposed whilst limiting disease burden to that observed in the VSV-only scenario, though results are sensitive to vaccine properties (e.g. efficacy), health system capabilities (e.g. vaccination rollout speed) and the assumed timeline to VSV availability. Our modelling suggests that availability of a BPSV for those aged 60+ years could have averted 40-65% of COVID-19 deaths during the pandemic's first year, though exact impact depends on the size of the maintained stockpile. Our work highlights significant potential impact of a BPSV, but that achieving this impact depends on investment into health systems enabling rapid and equitable access during future SARS-X pandemics.

Epidemiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how effective the Broadly Protective Sarbecovirus Vaccine (BPSV) will be in a possible future SARS - X epidemic. Specifically, the research aims to evaluate the potential effectiveness of BPSV in the following situations:

1. **Ring vaccination**: Evaluate whether BPSV can effectively control the outbreak of the epidemic through the ring vaccination strategy.
2. **Spatially - targeted vaccination**: Explore the role of BPSV in spatially - targeted vaccination, especially in large - scale vaccination in high - risk areas to reduce the disease burden.
3. **Large - scale vaccination of high - risk populations**: Study the effect of using BPSV in advance in high - risk populations, especially whether BPSV can significantly reduce the mortality rate before the specific virus vaccine (VSV) is available.

### Main research questions:
- **The effectiveness of BPSV in controlling the spread of the epidemic**: Especially for viruses similar to SARS - CoV - 1 and SARS - CoV - 2, can BPSV effectively control the spread of the epidemic?
- **The potential of BPSV in reducing mortality**: Especially before the development of VSV is completed, can BPSV significantly reduce the mortality rate in high - risk populations?
- **The effect of BPSV in reducing the need for non - pharmaceutical interventions (NPIs)**: Can the use of BPSV reduce the need for strict and long - term non - pharmaceutical intervention measures, thereby reducing the socio - economic costs?

### Research methods:
- **Mathematical modelling**: Use mathematical models to simulate the spread of the epidemic and the effectiveness of vaccination strategies in different scenarios.
- **Sensitivity analysis**: By changing the parameters in the model (such as vaccine efficacy, virus transmission rate, the intensity of NPIs, etc.), evaluate the impact of these factors on the effectiveness of BPSV.

### Key findings:
- **Ring vaccination**: For viruses similar to SARS - CoV - 1, the ring vaccination strategy of BPSV may effectively control the epidemic, but for viruses similar to SARS - CoV - 2, the effect is limited.
- **Spatially - targeted vaccination**: A highly sensitive monitoring system is required for effective implementation; otherwise, it is difficult to control the spread of the epidemic.
- **Large - scale vaccination of high - risk populations**: Using BPSV in advance in high - risk populations can significantly reduce the mortality rate, especially before the development of VSV is completed.

### Conclusions:
- **The potential value of BPSV**: BPSV has significant public health potential in future SARS - X epidemics, especially in reducing mortality and reducing the need for NPIs.
- **Challenges and suggestions**: To achieve the maximum benefit of BPSV, investment in diagnosis, monitoring and public health response capabilities is required to ensure rapid and fair vaccine distribution.

Through these studies, the paper emphasizes the importance of BPSV in future epidemic responses and proposes the conditions and strategies required to achieve its maximum effectiveness.